Out of 11 analysts covering AstraZeneca (NYSE:AZN), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 55% are positive. AstraZeneca has been the topic of 14 analyst reports since September 18, 2015 according to StockzIntelligence Inc. Jefferies upgraded the stock on September 12 to “Buy” rating. Below is a list of AstraZeneca plc (ADR) (NYSE:AZN) latest ratings and price target changes.
12/09/2016 Broker: Jefferies Old Rating: Hold New Rating: Buy Upgrade
29/08/2016 Broker: Argus Research Old Rating: Hold New Rating: Buy New Target: $38.00 Upgrade
02/05/2016 Broker: Leerink Swann Rating: Market Perform Old Target: $38.00 New Target: $34.00 Maintain
15/03/2016 Broker: Jefferies Old Rating: Buy New Rating: Hold Downgrade
The stock decreased 1.50% or $0.5 on September 13, hitting $32.74. About 5.67 million shares traded hands or 11.83% up from the average. AstraZeneca plc (ADR) (NYSE:AZN) has risen 15.86% since February 8, 2016 and is uptrending. It has underperformed by 0.63% the S&P500.
AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of $82.87 billion. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 37.29 P/E ratio. The Firm has its activities in over 100 countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.